Evidence map›Paper›PMID 28619097›Full record

ReviewStem cell research & therapy2017

Adipose tissue-derived stromal vascular fraction in regenerative medicine: a brief review on biology and translation.

Pablo Bora, Anish S Majumdar

3 registry-linked trialsOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Stem cell research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 283 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
283citing papers in PubMed, 9 pooled it
22.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04255004 nacompletednot on this map

Autologous Peripheral Blood Mononuclear Cells for Limb Salvage in Diabetic Foot Patients With No-option Critical Limb Ischemia

TypeinterventionalSponsorOspedale San DonatoRan2014 to 2019Enrolled76ConditionsCritical Limb Ischemia, Diabetic FootArmsPall Celeris System, point of care device for human cell therapy
NCT07094958 nanot yet recruitingnot on this mapstarted 2025, after this paper: background citation

Efficacy of Intradermal Stromal Vascular Fraction Injection in the Treatment of Atrophic Acne Scar

TypeinterventionalSponsorSeoul National University HospitalRan2025 to 2026Enrolled16ConditionsAcne Scars, Acne Scars - AtrophicArmsstromal vascular fraction (SVF), Normal Saline (NS)
NCT07255547 phase4active not recruitingnot on this mapstarted 2019, after this paper: background citation

Arthrosocpic Treatment of Knee Chondral Lesions: Clinical, MRI and Histologic Comparison Between the Use of PRP vs ADSCs in Addition to Marrow Stimulation Techniques

TypeinterventionalSponsorUniversità degli Studi dell'AquilaRan2019 to 2026Enrolled80ConditionsKnee Chondral LesionArmsBone Marrow Stimulation, stromal vascular fraction (SVF), PRP injection
3 · Its place in the literature

Who cites it

283 citing papers in PubMed, 9 syntheses or guidelines pooled it, 522 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. The investigation and comparison of the efficacy and safety of stromal vascular fraction (SVF), platelet rich plasma (PRP), and 1064-nm Q-switched Nd:YAG laser in reducing nanofat treated infraorbital dark circles and wrinkles: A controlled blinded randomized clinical trial.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024
    Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Article

223 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Pablo BoraStempeutics Research Private Limited, Akshay Tech Park, # 72&73, 2nd Floor, EPIP Zone, Phase 1, Whitefield, Bangalore, 560066, India.
Anish S MajumdarStempeutics Research Private Limited, Akshay Tech Park, # 72&73, 2nd Floor, EPIP Zone, Phase 1, Whitefield, Bangalore, 560066, India. anish.majumdar@stempeutics.com.
Stempeutics (India) · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adipose/fat tissue provides an abundant source of stromal vascular fraction (SVF) cells for immediate administration and can also give rise to a substantial number of cultured, multipotent adipose-derived stromal cells (ADSCs). Recently, both SVF and ADSCs have gained wide-ranging translational significance in regenerative medicine. Initially used for cosmetic breast enhancement, this mode of treatment has found use in many diseases involving immune disorders, tissue degeneration, and ischaemic conditions. In this review, we try to address several important aspects of this field, outlining the biology, technology, translation, and challenges related to SVF- and ADSC-based therapies. Starting from the basics of SVF and ADSC isolation, we touch upon recently developed technologies, addressing elements of novel methods and devices under development for point-of-care isolation of SVF. Characterisation of SVF cells and ADSCs is also an evolving area and we look into unusual expression of CD34 antigen as an interesting marker for such purposes. Based on reports involving different cells of the SVF, we draw a potential mode of action, focussing on angiogenesis since it involves multiple cells, unlike immunomodulation which is governed predominantly by ADSCs. We have looked into the latest research, experimental therapies, and clinical trials which are utilising SVF/ADSCs in conditions such as multiple sclerosis, Crohn's disease, peripheral neuropathy, osteoarthritis, diabetic foot ulcer, and so forth. However, problems have arisen with regards to the lack of proper regulatory guidelines for such therapies and, since the introduction of US Food and Drug Administration draft guidelines and the Reliable and Effective Growth for Regenerative Health Options that Improve Wellness (REGROW) Act, the debate became more public with regards to safe and efficacious use of these cells.

Indexed as

Adipose TissueAnimalsCrohn DiseaseDiabetic FootHumansMultiple SclerosisMultipotent Stem CellsOsteoarthritisPeripheral Nervous System DiseasesRegenerative MedicineStromal CellsCD34Multipotent-stromal cellsPoint-of-care biomedical devicesRegenerative medicineRegulation of stem cell therapeuticsStromal vascular fraction

Identifiers

PMID28619097
PMCPMC5472998
OpenAlexW2625285338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.